Patients using Accolade, Proponent, Essentio, Altrua 2 Standard Life and Altrua 2 Extended Life pacemakers, as well as Visionist and Valitude cardiac resynchronization therapy pacemakers, may need to have their devices replaced earlier than anticipated, according to the FDA’s Dec. 16 alert.
Two deaths have been reported in association with these devices, according to Boston Scientific.
The FDA recommends providers monitor patients using these pacemakers. If a patient exhibits symptoms that suggest the device may have initiated safety mode, surgery should be scheduled to replace the device.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
